In:
APMIS, Wiley, Vol. 125, No. 11 ( 2017-11), p. 996-1006
Abstract:
Angiomotin ( AMOT ) promotes angiogenesis and plays a role in neovascularization during tumorigenesis. Recently, the AMOT isoform, AMOT ‐p130, was shown to exert a regulatory effect on Yes‐associated protein 1 ( YAP 1), a major downstream effector of the Hippo pathway. The specific roles of AMOT ‐p130 and YAP 1 in advanced gastric cancer ( AGC ) are yet to be established. In this study, a total of 166 patients with AGC were enrolled, and AMOT ‐p130 and YAP 1 levels were analyzed by immunohistochemistry using tissue microarrays. Low AMOT ‐p130 together with high YAP 1 expression (n = 30, 18.1%) was associated with high T stage (p = 0.042), high TNM stage (p = 0.025), and venous invasion (p = 0.048). A Kaplan–Meier survival analysis with log‐rank test revealed a significant correlation with decreased AMOT ‐p130 coupled with high nuclear YAP 1 expression with shorter overall survival (p = 0.0045) and disease‐free survival (p = 0.0028). Furthermore, multivariate analyses showed that the low AMOT ‐p130/high YAP 1 expression profile was an independent prognostic factor for disease‐free survival (p = 0.008, HR = 1.874, CI , 1.177–2.986) and overall survival (p = 0.012, HR = 1.903, CI , 1.152–3.143). Our findings collectively demonstrate that low AMOT ‐p130 combined with high YAP 1 expression is correlated with an unfavorable AGC prognosis.
Type of Medium:
Online Resource
ISSN:
0903-4641
,
1600-0463
DOI:
10.1111/apm.2017.125.issue-11
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2098213-6
SSG:
12
Bookmarklink